Sana Biotechnology
SANASana Biotechnology is a clinical-stage biotechnology company focused on creating engineered cells as a transformative class of medicine to repair and replace damaged tissues.
Earnings
Next report
Aug 10, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Sana Biotechnology is a clinical-stage biotechnology company focused on creating engineered cells as a transformative class of medicine to repair and replace damaged tissues. The company leverages proprietary ex vivo and in vivo cell engineering platforms to address diseases at their root cause, with a primary focus on type 1 diabetes, oncology, and autoimmune disorders. Their core value proposition lies in overcoming immune rejection and achieving cell-specific delivery of genetic payloads to enable off-the-shelf cellular therapies.
Sana is a pioneer in hypoimmune cell engineering and fusogen-based delivery, holding a significant intellectual property portfolio across both ex vivo and in vivo modalities.
Questions, answered.
- What is Sana Biotechnology's market cap?
- Sana Biotechnology (SANA) has a market capitalization of $912.8M and trades on NASDAQ.
- Who are Sana Biotechnology's competitors?
- Sana Biotechnology's key competitors include CRISPR Therapeutics AG, Vertex Pharmaceuticals Inc., Allogene Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Sana Biotechnology partner with?
- Sana Biotechnology's notable partners include Harvard University, University of California, San Francisco, Washington University, and others.
- What subsidiaries does Sana Biotechnology have?
- Sana Biotechnology's subsidiaries include Cobalt Biomedicine, Inc..
- Where is Sana Biotechnology headquartered?
- Sana Biotechnology is headquartered in United States of America and employs approximately 328 people. It has been publicly traded since 2021.